What is the outlook for the Indian pharma companies in 2019? Analysts tend to think while the outlook is a bit murky in India but still many feel the worst may be over with FY16 seeing price regulations from the price regulator, FY 17 seeing demonetization and FY 18 the impact of switchover to Goods and ...
Read more: Pharma 2019: Expect more M&As, USFDA re-inspections, a normalized year despite domestic ...